Rabies

Veterinary Vaccines Market to Hit US$ ~13.09 billion by 2031 | Exclusive Report by Growth Plus Reports

Retrieved on: 
Tuesday, May 31, 2022
Poultry, Infection, Livestock, Vaccine, APPA, Health, US, Transport, Ownership, Merck, American Pet Products Association, Vaccination, Rabies, Zoonosis, Intention, Awareness, Government, Bee, Human, Row, Animal, Growth, Aquaculture, Disease, Pet

The global veterinary vaccines market has been analyzed from three different perspectives Animal Type, Vaccine Type, and Region.

Key Points: 
  • The global veterinary vaccines market has been analyzed from three different perspectives Animal Type, Vaccine Type, and Region.
  • However, the high costs associated with vaccine development and storage & handling remain a major concern for the growth of the veterinary vaccines market.
  • The global veterinary vaccines market has been segmented majorly into two distinct categories depending on animal type, viz.
  • The companion animals segment is expected to be the fastest growing segment in the veterinary vaccines market.

Bavarian Nordic Enters Additional Vaccine Contracts with Governments in Response to Monkeypox Outbreak

Retrieved on: 
Monday, May 30, 2022
Royal commission, Risk, Company, Population, OMX, EBITDA, Ageing, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Bavarian Nordic, European Commission, Investment, Goal, Monkeypox, Vaccine, Government, Smallpox vaccine, COVID-19, Tick-borne encephalitis, Vaccination, Research, Rabies, FDA, Johnson & Johnson, Janssen Pharmaceuticals, Smallpox, Immunization, Immunodeficiency, Forward-looking statement, Modified vaccinia Ankara, Health Canada, Respiratory syncytial virus, Immune system, DKK, RSV, CEO, Pharmaceutical industry

Bavarian Nordic is currently in dialogue with additional countries concerning supply of the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness.

Key Points: 
  • Bavarian Nordic is currently in dialogue with additional countries concerning supply of the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness.
  • Bavarian Nordic has ongoing supply contracts with USA and Canada and has delivered the vaccine to a number of undisclosed countries globally as part of their national biological preparedness.
  • In recent years, the vaccine has been supplied in response to sporadic cases of monkeypox.
  • The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe.

Bavarian Nordic Enters First Larger Vaccine Contract with Government in Response to Monkeypox Outbreak

Retrieved on: 
Wednesday, May 25, 2022
Royal commission, Risk, Company, Population, OMX, EBITDA, Ageing, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Bavarian Nordic, European Commission, Investment, Goal, Monkeypox, Vaccine, Government, Smallpox vaccine, COVID-19, Tick-borne encephalitis, Vaccination, Research, Rabies, FDA, Johnson & Johnson, Janssen Pharmaceuticals, Smallpox, Immunization, Immunodeficiency, Forward-looking statement, Modified vaccinia Ankara, Health Canada, Respiratory syncytial virus, Immune system, DKK, RSV, CEO, Pharmaceutical industry

Bavarian Nordic is currently in dialogue with several other governments concerning supply of the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness.

Key Points: 
  • Bavarian Nordic is currently in dialogue with several other governments concerning supply of the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness.
  • Officially, monkeypox cases have been reported in more than 15 countries as of to-date with numbers continuing to rise.
  • In recent years, the vaccine has been supplied in response to sporadic cases of monkeypox.
  • The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe.

The Arizona Humane Society Was the Most Recent Recipient of Earnhardt Auto Centers No Bull Charities - Employee Contributions Program

Retrieved on: 
Friday, May 20, 2022
Tex Earnhardt, High society, Papago Park, Gap, Organic, Bull, Emergency, Charitable organization, Rabies, Cat, PETS, Marketing, Institution, Corporation, Humane society, Animal, Dog, GLOBE, Management, Insurance, Earnhardt, Phoenix

PHOENIX, May 20, 2022 (GLOBE NEWSWIRE) -- No Bull Charities - Employee Contributions is an ongoing effort that allows Earnhardt Auto Centers' employees to pool their resources to help area charities; the most recent recipient being the Arizona (AZ) Humane Society!

Key Points: 
  • PHOENIX, May 20, 2022 (GLOBE NEWSWIRE) -- No Bull Charities - Employee Contributions is an ongoing effort that allows Earnhardt Auto Centers' employees to pool their resources to help area charities; the most recent recipient being the Arizona (AZ) Humane Society!
  • Small, voluntary paycheck deductions towards No Bull Charities - Employee Contributions add up to significant funding for exemplary causes such as the AZ Humane Society.
  • As noted, No Bull Employee Charities is an ongoing effort that allows Earnhardt Auto Centers' employees to pool their resources to help local charities.
  • Earnhardt Auto Centers has been a family auto dealer in the Valley since our founder, Tex Earnhardt, opened his first dealership back in 1951.

Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases

Retrieved on: 
Thursday, May 19, 2022
Company, Disease, OMX, Bavarian Nordic, Infection, Monkeypox, Vaccine, Smallpox vaccine, Nasdaq Copenhagen, COVID-19, Tick-borne encephalitis, Rabies, FDA, Johnson & Johnson, Janssen Pharmaceuticals, Smallpox, Society, Travel, Respiratory syncytial virus, Infection prevention and control, Immune system, Government, Fatality, RSV, CEO, Pharmaceutical industry

The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic.

Key Points: 
  • The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic.
  • Subsequently, more than 20 cases have been confirmed across England, Portugal and Spain with additional suspected cases currently being investigated.
  • In the US, a single case has been confirmed in a traveler from Canada, where no cases are yet confirmed, but several remain under investigation.
  • The vaccine is approved in Europe as IMVANEX for only the smallpox indication but has previously been provided for off-label use in response to monkeypox cases.

Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exercise of Contract Option by the U.S. Government

Retrieved on: 
Wednesday, May 18, 2022
Department, HHS, Assistant, Biomedical Advanced Research and Development Authority, Office of Inspector General, U.S. Department of Health and Human Services, Company, OMX, Bavarian Nordic, Exercise, Goal, Contract, Government, Vaccine, Monkeypox, Smallpox vaccine, USD, COVID-19, Tick-borne encephalitis, Performance-based contracting, Rabies, FDA, Johnson & Johnson, Janssen Pharmaceuticals, Partnership, Smallpox, U.S. Department of Defense Strategy for Operating in Cyberspace, Vaccinia, Forward-looking statement, Office of the Assistant Secretary for Preparedness and Response, Immune system, Development, United States Department of Health and Human Services, BARDA, CEO, Pharmaceutical industry

The majority of the bulk vaccine for these doses has already been manufactured and invoiced.

Key Points: 
  • The majority of the bulk vaccine for these doses has already been manufactured and invoiced.
  • In parallel to these activities, we will, with the award of this first option, begin to manufacture and invoice freeze-dried JYNNEOS doses in 2023 and 2024.
  • This marks a significant milestone in our long-standing partnership with the U.S. government to ensure availability of life-saving vaccines for the entire population.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.

PetSmart Launches New Adventure-Ready Products from Arcadia Trail™ and Announces In-Store "Summer Demo Days" for Outdoor Exploration and Fun this Summer

Retrieved on: 
Monday, May 16, 2022
ID, Disease, Camping, Food, Pet, Environment, Multimedia, Collapsed in Sunbeams, Snack, Parent, Vaccine, Solution, PetSmart Charities, Swimming, COT, Abrasion, Rabies, PETS, Lyme disease, Bruise, Travel, Vomiting, Organization, Distemper, PetSmart, Nose, Skin, Friends, Water, Tick, Hunting

With new products from Arcadia Trail and in-store "Summer Demo Days," PetSmart offers the right gear and expert advice to help pet parents safely get outdoors with their pets.

Key Points: 
  • With new products from Arcadia Trail and in-store "Summer Demo Days," PetSmart offers the right gear and expert advice to help pet parents safely get outdoors with their pets.
  • Arcadia Trail launched in 2020 based on customer insights and trends showing pet parents are looking to include pets in their outdoor adventures.
  • *
    Arcadia Trail, one of more than 20 PetSmart proprietary brands, features products that are durable and tough enough for all activities, including camping, hiking and water play.
  • With the full lineup from Arcadia Trail, PetSmart has anything pet parents need to include their pets more safely in their summer adventures.

Enzolytics, Inc. Discusses the Significance and Revenue Potential of Its Therapeutic Platforms with The Stock Day Podcast

Retrieved on: 
Monday, May 16, 2022
Severe acute respiratory syndrome coronavirus 2, Company, Patent, Disease, COO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Infection, AI, Certification, Tetanus, News, Patient, Influenza, Antibody, Diphtheria, Interview, Neutralizing antibody, Rabies, Patent application, Intention, Partnership, Time, Oseltamivir, Toxicity, Virus, Budget, Prognosis, Drug development, Therapy, Immune system, HIV, HIV/AIDS, IPF, SEC, Drug discovery, Coronavirus, Vaccine, Oil, Medical device, Pharmaceutical industry, Adenoviridae

Director and COO of the Company, Dr. Gaurav Chandra, joined Stock Day host Everett Jolly.

Key Points: 
  • Director and COO of the Company, Dr. Gaurav Chandra, joined Stock Day host Everett Jolly.
  • Dr. Chandra then elaborated on the significance of IPF Immune, citing positive results during testing against the CoronaVirus (SARS-CoV-2) strain 229e.
  • Additionally, he said that our preliminary studies with IPF-Immune have demonstrated significant in-vitro neutralization activity against Adenovirus.
  • "We have identified the conserved immutable targets in about 20 viruses, and then we went a bit further," said Dr. Chandra.

Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments

Retrieved on: 
Thursday, May 12, 2022
Janssen, Research, Webcast, Form 10-K, Antibody, Virus-like particle, Income, Investor relations, Energy Independence and Security Act of 2007, SEC, Therapy, Clinical trial, CGMP, COVID-19, Mouse, Securities Act of 1933, RBD, Mab, Third party, Fungus, GLOBE, Company, White House, Rabies, National Institute, Infection, Insurance, Vaccine, American Rescue Plan Act of 2021, Human, White House Coronavirus Task Force, Securities Exchange Act of 1934, Protein, Severe acute respiratory syndrome coronavirus 2, Population, Patient, NASDAQ, Cannabinoid, D, Antigen, Safety, Pharmaceutical industry, Online gambling, Fine chemical, Life insurance, Omicron, Phibro, Dyadic, C1

We look forward to providing future updates as we advance our commercial initiatives across the companys programs," concluded Mr. Emalfarb.

Key Points: 
  • We look forward to providing future updates as we advance our commercial initiatives across the companys programs," concluded Mr. Emalfarb.
  • Phibro Animal Health On February 10, 2022, Dyadic entered into an exclusive license agreement for a Phibro targeted disease.
  • The Company has successfully completed the initial phase of the project and is currently moving into the second phase to further increase productivity.
  • Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise.

Curative Biotechnology, Inc. Names Cary Sucoff to Board of Directors

Retrieved on: 
Thursday, May 12, 2022
Binghamton University, Company, Bar, New England Law Boston, Past, CD56, Committee on Finance, Board of directors, Neuro, Historical annual reformulations of the influenza vaccine, BOCA, Infection, City of London Finance Committee, Vaccine, OTC, OTC Markets Group, Judgement, Review, The National Law Review, Therapy, Degenerative disease, Comp, IMAC, Rabies, AMD, Securities Act of 1933, Securities Exchange Act of 1934, Industry, Trustee, Director, Audit, Glaucoma, Compliance, Board, Metformin, Technology, Neoplasm, Law review, Movement, Schizophrenia, Pharmaceutical industry, Financial adviser, Fine chemical, Medical device, Biotechnology, Walmart, Glioblastoma, Tel Aviv University

BOCA RATON, Fla., May 12, 2022 /PRNewswire/ -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Cary Sucoff has joined its Board of Directors as an independent director.  With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies. Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees.

Key Points: 
  • BOCA RATON, Fla., May 12, 2022 /PRNewswire/ -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Cary Sucoff has joined its Board of Directors as an independent director.
  • Since 2011, Mr. Sucoff has owned and operated Equity Source Partners LLC, an advisory and consulting firm.
  • In addition, Mr. Sucoff currently serves as an advisor to:
    Sapience Therapeutics, Inc. - a Phase 1/2 Biotech company focusing on Glioblastoma.
  • Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases.